| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Alzamend Neuro, Inc. (ALZN) has 3 insiders with recent SEC Form 4 filings, including 11 buys and 0 sells. ALZN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 25 | $26.00 | - | |
| Dir | 0 | - | - | |
| Dir | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2025 | Ault Milton C III | Director, 10% Owner | Buy | 100 | $0.68 | $68.42 | +0.1% | -44.9% | -65.3% | |
| Aug 6, 2024 | Ault Milton C III | Director, 10% Owner | Buy | 75 | $2.75 | $206.25 | - | -27.9% | -89.0% | |
| Jul 31, 2024 | Ault Milton C III | Director, 10% Owner | Buy | 25 | $3.74 | $93.42 | - | -55.2% | -93.0% | |
| Apr 19, 2024 | Ault Milton C III | Director, 10% Owner | Buy | 1,000 | $0.69 | $688.20 | +0.1% | -43.1% | -89.9% | |
| Apr 1, 2024 | Ault Milton C III | Director, 10% Owner | Buy | 334 | $0.91 | $304.24 | - | -53.6% | -88.7% | |
| Jan 5, 2024 | Ault Milton C III | Director, 10% Owner | Buy | 2,000 | $1.06 | $2,127.00 | +0.3% | -5.3% | -86.7% | |
| Jan 5, 2024 | Ault Milton C III | Director, 10% Owner | Buy | 5,000 | $1.02 | $5,092.50 | +0.7% | -5.3% | -86.7% | |
| Dec 26, 2023 | Ault Milton C III | 10% Owner | Buy | 700 | $0.91 | $634.84 | +0.4% | +12.1% | -86.2% | |
| Sep 26, 2023 | Katzoff David J | Chief Financial Officer | Buy | 53,000 | $0.19 | $10,234.30 | +189.3% | -68.6% | -94.5% | |
| May 24, 2023 | Ault Milton C III | 10% Owner | Buy | 18,000 | $0.59 | $10,704.60 | +4.9% | -50.8% | -93.3% |